Samsung BioLogics Co Ltd
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 207940.KQ | 001360.KS | 085660.KQ | 1FW1.F | 002630.KS | 1548.HK | |
|---|---|---|---|---|---|---|
| Market cap | — | 118.87B | 677.77B | 22.64B | 40.41B | 76.81B |
| P/E (TTM) | — | — | — | 37.9 | — | — |
| Forward P/E | — | — | — | — | — | 85.8 |
| Price/book | — | — | — | 3.5 | — | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −22.66% | −16.75% | −45.74% | +44.16% | −45.19% | +109.10% |
| Today | −1.76% | +0.08% | +5.96% | −0.90% | +13.87% | −0.94% |
The closest companies by business. Prices may be delayed up to 20 min.
Latest news
All 207940.KQ news ›Samsung Biologics Earns Top Rating in ESG Risk Assessment
Published 04 Nov.2026 08:51(KST) Samsung Biologics received the highest rating in a global environmental, social and governance (ESG) risk assessment. A view of Samsung Biologics Plant 4 in Songdo, Yeonsu-gu, Incheon. Samsung Biologics. On…
Samsung Biologics shares up 1.7% after $325 mil. CMO deal
Korea Biomedical Review Samsung Biologics shares rose 1.69 percent on Tuesday after the company said it signed a $324.8 million contract manufacturing organization (CMO) deal with a global pharmaceutical company. The stock traded at…
Samsung Biologics Executes 97.99% PolyPeptide Takeover to Claim Peptide Dominance
The global contract development and manufacturing organization landscape is shifting fast. Biopharmaceutical pipelines are moving toward complex synthetic peptides and multi modality therapeutics. In a major milestone for cross border…
Samsung Biologics secures $325 million CDMO deal, boosts Korea's biotech reach
Long-term CDMO pact through 2031 strengthens Samsung Biologics' order backlog and global footprint Samsung Biologics(207940) said in a filing on the 3rd that it signed a $324.8 million (about 434.3 billion won) contract with a global…
Samsung Biologics Secures 97.66% of PolyPeptide Shares in Tender Offer
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services. The deal follows a broader shift toward complex modalities at the company. In an earlier BioPharm…
Samsung Biologics signs 434.3 billion won deal with global pharma firm, surpasses 30 trillion won in cumulative orders
8:54 a.m. Nov 3, 2026 Samsung Biologics emphasized that it maintains close cooperative relationships with numerous partners, including the majority of the top 20 global pharmaceutic
South Korea's Samsung Biologics Signs $324.8 Million CMO Deal With Global Pharma; Cumulative Orders Top $22.3 Billion
Samsung Biologics has signed a new 434.3 billion won (about $322.9 million) contract manufacturing organization (CMO) deal for biopharmaceuticals with a global pharmaceutical company, pushing its cumulative orders since founding past 30…
Samsung Biologics Reports Third Quarter 2026 Financial Results
Clear and cool overnight; a little patchy frost in a few spots. . headline: Freeze Watch from SAT 12:00 AM EDT until SAT 9:00 AM EDT INCHEON, South Korea, Oct. 21, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract…
Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth
22 October 2026 | Thursday | Company results Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the third quarter of fiscal year 2026. [Consolidated…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- en.sedaily.com10
- biz.chosun.com6
- finance.biggo.com4
- tradingview.com4
- prnewswire.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 51 articles, not a forecast.